Newsroom | 12738 results

ミネアポリス--(BUSINESS WIRE)--（ビジネスワイヤ） -- Edison®（エジソン）ヒストトリプシー・システムおよび新規ヒストトリプシー治療プラットフォームの開発企業であるヒストソニックスは、K5グローバル、ベゾス・エクスペディションズ、ウエリントン・マネージメント、および新規・既存の投資家を含むグローバルに認知された民間・公的投資家のシンジケートによる経営陣主導の過半数株式取得を発表しました。取引によりヒストソニックスは約22億5000万ドルの評価を受け、新規臨床適応とグローバル市場におけるエジソン・システムの成長加速が可能になります。 ヒストソニックスは、社長兼最高経営責任者（CEO）のマイク・ブルーと経営陣が引き続き率いていきます。ブルーは取引完了後、取締役会会長を兼務します。 「当社が企業として徹底して重視してきたのは、スピードと規模、そして今あるどの選択肢よりも優れた治療法を患者にいち早く提供することです」とブルーは述べています。「新たなパートナーとなるこのグループは、業界全体を変革するカテゴリー定義企業を支援してきました。支援により企業としての水準が向上...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the second quarter ended June 30, 2025. “In the second quarter of 2025, AVMAPKI FAKZYNJA CO-PACK became the first-ever treatment approved by the FDA specifically for use in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, and we are of...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. “The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m...

TORONTO--(BUSINESS WIRE)--ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from both the U.S. Food and Drug Administration (FDA) and Health Canada to initiate a Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of its lead candidate, PQ203. The FDA has also granted PQ203 Fast Track designation for patients with triple negative breast cancer, recognizing the therapy’s potent...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, l’impresa che ha creato il sistema di istotripsia Edison® e l’innovativa piattaforma per la terapia con questa tecnica, oggi ha annunciato l’acquisizione della partecipazione di maggioranza guidata dal management da parte di un consorzio di investitori pubblici e privati rinomati globalmente – K5 Global, Bezos Expeditions e Wellington Management nonché altri investitori preesistenti e nuovi. L’operazione assegna a HistoSonics un valore di circa 2,25 mi...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, Entwickler des Edison® Histotripsy-Systems und einer neuartigen Histotripsy-Therapieplattform, gab heute bekannt, dass eine Gruppe weltweit anerkannter privater und öffentlicher Investoren, darunter K5 Global, Bezos Expeditions, Wellington Management sowie weitere neue und bestehende Investoren, unter Führung des Managements eine Mehrheitsbeteiligung erworben hat. Die Transaktion bewertet HistoSonics mit rund 2,25 Mrd. USD und versetzt das Unternehmen...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, de ontwikkelaar van het Edison® histotripsy-systeem en een nieuw histotripsy-behandelplatform, heeft vandaag bekendgemaakt dat een consortium van wereldwijd erkende particuliere en publieke investeerders, waaronder K5 Global, Bezos Expeditions, Wellington Management en andere nieuwe en bestaande investeerders, een meerderheidsbelang in het bedrijf heeft verworven. Met de transactie die HistoSonics op ongeveer 2,25 miljard dollar waardeert, kan het bedr...

MINNEÁPOLIS--(BUSINESS WIRE)--HistoSonics, desarrollador del sistema de histotricia Edison® y de la novedosa plataforma de terapia de histotricia, ha anunciado hoy la adquisición de una participación mayoritaria liderada por la dirección de un sindicato de inversores privados y públicos reconocidos en todo el mundo, incluyendo K5 Global, Bezos Expeditions, Wellington Management y otros inversores nuevos y existentes. La transacción otorga a HistoSonics un valor aproximado de 2250 millones de dó...